| IM19 CAR-T cells / Beijing Imunopharm, Simcere |
NCT04440436: Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients |
|
|
| Recruiting | 1/2 | 52 | RoW | IM19 CAR-T Cells, Fludarabine, Cyclophosphamide | Beijing Immunochina Medical Science & Technology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd. | NHL | 06/22 | 06/35 | | |
NCT05155215: Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma |
|
|
| Not yet recruiting | 1/2 | 68 | NA | IM19 CAR-T cells, Cyclophosphamide, Fludarabine | Beijing Immunochina Medical Science & Technology Co., Ltd. | Lymphoma, Lymphoma, Mantle-Cell, Neoplasms by Histologic Type, Neoplasms, Lymphoproliferative Disorders | 12/22 | 02/23 | | |
NCT05309213: Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia |
|
|
| Not yet recruiting | 1/2 | 58 | NA | IM19 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Leukemia | 04/25 | 06/25 | | |
NCT05480501: Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 9 | RoW | IM19 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Leukemia | 08/24 | 10/24 | | |
NCT04336501: Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation |
|
|
| Recruiting | N/A | 20 | RoW | IM19 CAR-T | Beijing Immunochina Medical Science & Technology Co., Ltd. | Leukemia | 12/21 | 12/21 | | |